View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 8, 2020

Japanese regulator approves Gilead’s remdesivir to treat Covid-19

Gilead Sciences has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug remdesivir, under the brand name Veklury, to treat Covid-19 infection.

Gilead Sciences has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug remdesivir, under the brand name Veklury, to treat Covid-19 infection.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The decision falls under an exceptional approval pathway, which is similar to emergency use authorisation in the US.

Remdesivir is an experimental nucleotide analogue that showed broad-spectrum antiviral activity against various viral pathogens, including Ebola, Marburg, MERS and SARS, in-vitro and in-vivo in animal models.

In-vitro testing found that the drug is active against SARS-CoV-2, the novel coronavirus that causes Covid-19. The drug is currently being assessed in several Phase III clinical trials.

Gilead Sciences chief medical officer Merdad Parsey said: “The Japanese approval of remdesivir is in recognition of the urgent need to treat critically ill patients in Japan. It is a reflection of the exceptional circumstances of this pandemic.

“We thank the Japanese Ministry of Health, Labour and Welfare for their leadership and collaboration, as we together work to respond to this public health emergency.”

The Japanese approval is supported by results from the US National Institute of Allergy and Infectious Diseases (NIAID)’s global Phase III trial and Gilead’s Phase III SIMPLE trial in patients with severe Covid-19 manifestations.

Preliminary data from NIAID’s study, called ACTT, showed a 31% faster time to recovery in patients treated with Gilead’s drug when compared to placebo.

According to the top-line results from Gilead’s SIMPLE study, patients on a ten-day treatment course experienced an improvement in a clinical status similar to those on a five-day dosing course.

In addition, the MHLW based its decision on available data from Gilead’s compassionate use programme, which also involved patients in Japan.

Remdesivir is yet to be licensed or approved outside of Japan and Gilead is working with regulatory authorities globally to facilitate appropriate access to the drug.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology